Thrivent Financial for Lutherans

Position in FATE — Fate Therapeutics Inc

CIK 314984 Minneapolis, MN

Position in FATE

as of Mar 31, 2026 · filed May 1, 2026 Compact

Position Value

$40,925

+$7,503 QoQ

Shares Held

34,105

0.0% QoQ

Ownership

0.029%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2024

8 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Thrivent Financial for Lutherans holds $270,833,554 across 48 Biotechnology names. FATE ranks #47 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	EXEL	Exelixis, Inc.	1,568,627	$67,278,411
2	BMRN	Biomarin Pharmaceutical Inc	627,699	$35,458,716
3	VRTX	Vertex Pharmaceuticals Inc / Ma	75,977	$33,926,767
4	RPRX	Royalty Pharma plc	499,167	$23,945,040
5	TECH	BIO-TECHNE Corp	302,934	$15,831,330
6	ARGX	Argenx SE	12,682	$9,261,030
7	ALNY	Alnylam Pharmaceuticals, Inc.	20,470	$6,772,908
8	REGN	Regeneron Pharmaceuticals, Inc.	8,440	$6,521,080

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$40,925	34,105	0.0%	Shares	Defined	2026-05-01
2025-12-31	$33,422	34,105	0.0%	Shares	Defined	2026-02-05
2025-09-30	$42,972	34,105	-8.1%	Shares	Defined	2025-11-04
2025-06-30	$41,569	37,116	-58.4%	Shares	Defined	2025-08-26
2025-03-31	$70,564	89,322	0.0%	Shares	Defined	2025-08-26
2024-12-31	$147,381	89,322	-28.8%	Shares	Defined	2025-02-10
2024-09-30	$438,795	125,370	+24.7%	Shares	Sole	2024-11-07
2024-06-30	$329,856	100,566	—	Shares	Sole	2024-08-13
No filing history on record for this holder in this stock.